ROSEN, SKILLED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm

New York, NY–(Newsfile Corp. – December 29, 2024) – WHY? The Rosen Law Firm, a global investor protection law firm, announces that it has filed a class action lawsuit on behalf of purchasers of AstraZeneca PLC (NASDAQ: LON: ) securities from February 23, 2022 to December 17, 2024, both dates including (“Class Period”) A class action has already been filed. If you want to act as the main plaintiff, you must move to court no later than February 21, 2025 In a securities classification application filed for the first time by a company.

SO WHAT? If you purchased AstraZeneca (NASDAQ: ) securities during the Class Period, you may be entitled to a refund without paying any cash fees or expenses through a contingency fee arrangement.

WHAT TO DO NEXT? To join the AstraZeneca course, visit https://rosenlegal.com/submit-form/?case_id=1331 or call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com. A class action lawsuit has already been filed. If you want to act as the main plaintiff, you must move to court no later than February 21, 2025. The lead plaintiff is the representative party acting on behalf of other class members, leading the litigation.

WHY CHOOSE ROSEN LAW? We encourage investors to choose qualified advisors with a track record of success in leadership roles. Often, notifying firms do not have comparable experience, resources, or the recognition of any meaningful partner. Rosen Law Firm represents investors worldwide, focusing its practice on securities in class action and shareholder derivative litigation.The Rosen Law Firm won what was then the largest securities class action against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action: (WA:) Services for securities class actions in 2017. The company has been ranked in the top 4 every year since 2013. In 2019 alone, the company secured more than 438 million dollars for investors Founding partner Lawrence Rosen was named a titan of plaintiffs’ counsel by law360.Many of the firm’s attorneys have been recognized By Lawdragon and Super Lawyers.

DETAILS OF THE CASE. According to the lawsuit, the defendants made materially false and/or misleading statements throughout the Class Period and/or failed to disclose that: (2) as a result, AstraZeneca faced increased legal exposure in China, which ultimately resulted in AstraZeneca’s China President being arrested by Chinese law enforcement agencies; (3) as a result, AstraZeneca underestimated its legal risks; (4) the foregoing, if disclosed, could materially harm AstraZeneca’s business operations in China; and (5) as a result, Defendants’ statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the real details hit the market, the lawsuit alleges, investors suffered losses.

To join the AstraZeneca course, visit https://rosenlegal.com/submit-form/?case_id=1331 call Philip Kim, Esq. Toll free at 866-767-3653 or email case@rosenlegal.com.

No class has been certified. Unless you are represented by an attorney. You may choose to remain a member of the class and do nothing at this time potential future recovery is not dependent on serving as lead plaintiff.

Follow us for updates on LinkedIn at https://www.linkedin.com/company/the-rosen-law-firm or on Twitter at https://twitter.com/rosen_firm or on Facebook (NASDAQ: ). https:/ /www.facebook.com/rosenlawfirm.

Advertisement of a lawyer. Previous results do not guarantee a similar result.

——————————

Contact information.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/235453